Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sotatercept in Japanese Participants With Pulmonary Arterial Hypertension
NCT05818137Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2023
- Primary completion
- Mar 2024
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sotatercept in pulmonary arterial hypertension (PAH), sponsored by Merck & Co. Primary endpoints: Pulmonary Vascular Resistance at 24 weeks, Adverse Events at 24 weeks and 1 more. Started May 2023; status: completed.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05818137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05818137.